Efecto de la Vacuna del Papiloma Humano en la prevención del cáncer cervicouterino: Metaanálisis

The aim of this review is to analyze and evaluate the efficacy of the prophylactic vaccine against human papilloma virus to prevent cervical cancer. This was accomplished through a research in MEDLINE for controlled and randomized clinical trials that evaluated the efficacy of the bivalent and quadrivalent vaccine against the development of CIN lesions. The bivalent vaccine Cervarix lowered the risk 19.35% (0.24 [0.13-0.44]), the active bivalent 2% (0.02 [0.00-0.28). The quadrivalent vaccine Gardasil 16% (0.19 [0.08-0.48]) and the active quadrivalent 3% (0.03 [0.01-0.08). These results show that the treatment group always had a positive outcome compared to the control group and both vaccines are effective to reduce the development of CIN+ lesions.